600329.SS
600329.SS
CNE000001808
TIANJIN PHARMACEUTICAL DA REN T
Loading chart...

Company Profile

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. The company was founded in 1915 and is based in Tianjin, the People's Republic of China.

Related stocks

002603.SZ
002603.SZ • China
YILING
15.53 CNY
3.88B USD 1Y -4.1%
000661.SZ
000661.SZ • China
CCHN
71.9 CNY
4.39B USD 1Y -44.4%
300142.SZ
300142.SZ • China
WALVAX
14.75 CNY
3.53B USD 1Y +26%
600079.SS
600079.SS • China
HUMANWELL HEALTHCARE (GROUP) CO
19.23 CNY
4.7B USD 1Y -10.1%
000739.SZ
000739.SZ • China
APELOA PHARMA.
25.4 CNY
4.4B USD 1Y +55.9%
000623.SZ
000623.SZ • China
JLAD
17.53 CNY
3.14B USD 1Y -13.7%
300558.SZ
300558.SZ • China
BETTA
48.43 CNY
3.07B USD 1Y -29.3%
2096.HK
2096.HK • China
SIMCERE PHARMA
10.89 HKD
3.56B USD 1Y -13.7%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
37.5% p.a.
Max Drawdown (5Y)
-55.1%
Sharpe Ratio (5Y)
0.11
Beta Factor
0.46
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (37.5% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -55.1% in the extended horizon.
ende